北科生物Beike Biotechnology  
深圳市北科生物科技有限公司（简称北科生物），是中国专业从事干细胞基础研究、临床应用研究及干细胞技术服务的生物高科技企业。在干细胞临床应用研究和技术服务等方面，北科生物始终和国际发展同步。北科生物对中国生物医学技术的发展具有强烈的使命感，旨在通过对干细胞基础研究和临床应用技术的持续、深入研究，使中国的生物医学产业在国际竞争中占据一席之地。

北科生物自2005年7月成立以来，凭借着其在干细胞基础研究和临床应用研究领域取得的积极成果，而备受国内外关注和好评。北科生物是一家拥有自主知识产权的生物企业，目前已拥有8项重要的发明专利，1项实用新型专利，其中2项获得授权。2006年9月深圳市科技和信息局授予北科生物为深圳市高新技术企业。

北科生物目前拥有员工约430名，其中56%以上为技术人员，拥有在干细胞研究领域成果卓越的多位院士及国内外学者领衔的专业技术研发团队。

北科生物在海内外投资成立了黑龙江省北科生物科技有限公司、辽宁北科生物科技有限公司、江苏省北科生物科技有限公司、上海祥晖生物科技有限公司、湖北省北科生物科技有限公司、北科国际（香港）有限公司、Beike Biotech India Pvt. Ltd.（印度）和Beike-Siricell Holdings Inc.（泰国）。

北科生物一直孜孜不倦地在拓展新的产业发展思路，得到了政府各界的大力支持。江苏北科即是借助政府各方面的支持，创建的一个崭新的、具有突破性的技术平台。江苏北科下设中国医药城北科干细胞研究院，并获得江苏省科技厅批准成立江苏省干细胞与生物治疗公共技术服务平台（下设江苏省干细胞库、江苏省生物治疗研究中心），获得江苏省发改委批准成立江苏省干细胞与再生医学工程中心，并且是江苏省卫生厅批准的江苏省干细胞与再生医学基地的主要承建单位。同时，在2005年12月公司得到深圳市政府支持成立了深圳市北科细胞工程研究所，在2008年12月获得深圳市科信局的立项支持成立了深圳市干细胞工程技术研究开发中心。

北科生物致力于干细胞技术从实验室到临床应用的一系列标准、规范和体系的建立和完善；致力于多种来源的成体干细胞的体外分离、培养、扩增、诱导、分化及鉴定的基础研究和临床应用研究；致力于多种干细胞组织工程产品的研究、开发，以及干细胞相关的药物筛选平台的建设；特别值得一提的是，在近两年国内外在干细胞领域取得突破性进展的iPS技术领域，公司拥有自主知识产权并决定在该研究领域投入巨资。目前，北科生物已在全国各地建立了多个符合GMP标准的细胞实验室，已启动ISO9001 质量管理体系认证，并积极参照AABB/FACT的相关标准，对公司现有质控体系进行完善和提高。

截至2009年，北科干细胞技术已经治疗病人6000多例，其中包括美国、加拿大、英国、匈牙利等40多个国家的500多名国外患者，获得了显著的治疗效果。

北科生物已与清华大学深圳研究生院、香港中文大学、郑州大学、匈牙利德布勒森大学及瑞典哥德堡大学等多所国内外知名学府建立了科研合作关系。这种广泛的国际、国内科研合作，有利于发挥各自优势，确立我们在干细胞基础研究和临床科研领域的国际领先地位。

北科生物将本着“严谨、创新、关爱、服务”的企业理念，为干细胞技术能够为人类健康造福而不懈追求！

Beike Biotechnology is a leading biotechnology company whose scientists have been dedicated to the development and commercialization of adult stem cell therapies since 1999. The company currently produces a full line of stem cell products derived from umbilical cord, cord blood, and bone marrow stem cells. Beike's proprietary processing and quality assurance technologies prepare the cells for use in treating a variety of serious medical conditions including ataxia, brain injury, cerebral palsy, diabetic foot disease, lower limb ischemia, multiple sclerosis, muscular dystrophy, spinal cord injury, and optic nerve damage.

Beike's stem cells are derived from healthy donors who are carefully screened for transmissible diseases. The samples are additionally screened by government appointed blood banks and Beike’s specialized laboratories. The stem cells are then banked in state-of-the-art facilities and only utilized in partnership with the best hospitals and physicians.

Stringent quality control procedures are undertaken at each of Beike‘s eighteen laboratories. Some of the laboratories are located inside the research departments of hospitals while others are located directly inside government blood banks. Beike also has two large stand alone laboratories where both research and stem cell processing take place. Beike, in partnership with the regional government, maintains a bank for the storage of stem cells located in the China Medical City in the Jiangsu province. This storage facility is capable of storing cord blood, cord mesenchymal, and iPS cells. All of the laboratories are outfitted with modern equipment and have been fully certified by the relevant drug authorities.

Treatment protocols include injections of umbilical cord blood stem cells, cord mesenchymal stem cells, and bone marrow mesenchymal stem cells directly into the spinal cord fluid and intravenously. However, for ailments like spinal cord injuries, liver disease, heart disease, muscular dystrophy, and lower limb ischemia, the stem cells are delivered through injections directly into the damaged tissue as well as through standard methods. For many diseases, protocols include rehabilitation and physical therapy.

Stem cells work by providing the body with paracrine and cytokines as well as a variety of other cell factors. These help to encourage the following functions:

1. Immune system regulation
2. Reducing cell death
3. Stimulation of growth of the patient’s own stem cells
4. Neo-angiogenesis (the growth of blood vessels resulting in increased blood flow to damaged areas)
5. Scar tissue reduction
6. Improving the effective conduction of intercellular electrical signals and transduction

Our research for future treatments is focused mainly on iPS technology in partnership with various leading scientific groups including Tsinghua Unversity. Beike’s scientists and partners have authored nearly eighty publications in Chinese scientific journals as well as ongoing clinical studies since our first ALS trial program in 2001. We very much welcome cooperation with international partners to help verify the effectiveness of our treatments and protocols and to license other technologies for use throughout our network of twenty seven hospitals。

The company was founded with capital from Beijing University, Hong Kong University of Science and Technology, and Shenzhen City Hall. The formation of the company was also supported with grants from the China State National Fund. Since that time, additional capital has been provided by a variety of Chinese venture capital firms.In total, Beike has received over US$6 million in Chinese government grants including a grant for a joint laboratory in Shenzhen with Tsingua University to focus on the study of stem cell reprogramming.

Beike‘s head office is located in Shenzhen but the company also has offices in Beijing, Nanjing, Taizhou, and Qingdao.

Stem Cell Processing Information

Umbilical Cord Blood (UCB) Stem Cells

For most ailments such as CP, ataxia, ALS, autism, and optic nerve hypoplasia, Beike's protocols utilize UCB stem cells. Our UCB stem cell doses consist of three subsets of stem cells. These are hematopoietic stem cells, endothelial progenitor cells, and mesenchymal stem cells. As has been shown in numerous studies, hematopoietic stem cells and endothelial progenitor stem cells are likely to form tissues in the body. Mesenchymal stem cells can assist in the growth of chondrocytes (a type of cell critical to tissue renewal, particularly cartilage), liver cells, kidney cells, and neurons, and also conduct repairs in relation to vascular disorders within the brain, ocular areas, and throughout the body including the heart, kidney, and pancreas.

Umbilical Cord Mesenchymal (UC-MSC) Stem Cells

Some of Beike's protocols, inclu